International Journal of Rheumatology / 2017 / Article / Tab 4

Review Article

Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis

Table 4


Study nameTrial/author, yearWas randomization carried out appropriately?Was the concealment of treatment allocation adequate?Were the care providers, participants, and outcome assessors blind to treatment allocation?Were the groups similar at the outset of the study in terms of prognostic factors, for example, severity of disease?Were there any unexpected imbalances in drop-outs between groups?Is there any evidence to suggest that the authors measured more outcomes than they reported?Did the analysis include an intention-to-treat analysis? If so, was this appropriate and were appropriate methods used to account for missing data?

BREVACTAKivitz, 2014;
Olech, 2013 (abstract)
YesYesYesYesNoNoYes
TOWARDGenovese, 2008UnclearUnclearYesYesNoNoYes
REALISTICWeinblatt, 2012YesYesYesYesNoNoYes
ROSEYazici, 2012UnclearUnclearYesYesNoNoYes
ACQUIREGenovese, 2011YesUnclearYesYesNoNoYes
AMPLEWeinblatt, 2013UnclearUnclearNoYesNoNoYes
AUGUST IIvan Vollenhoven, 2011YesYesYesYesNoNoYes
ACT–RAYDougados, 2013YesYesYesYesNoNoYes
ADACTAGabay, 2013YesYesYesYesNoNoYes
ABT-Kremer 1Kremer, 2003;
Kremer, 2005
YesYesYesYesNoNoUnclear
ABT-Kremer 2Kremer, 2006;
Russell, 2007
YesYesYesYesNoNoYes
ATTESTSchiff, 2008YesUnclearYesYesNoNoYes
ADA–Van de Putte 2Van de Putte, 2004YesYesYesYesNoNoYes
ADA–Van de Putte 1Van de Putte, 2003UnclearUnclearYesYesNoNoYes
ARMADAWeinblatt, 2003YesYesYesYesNoNoYes
ADA–KeystoneKeystone, 2004UnclearUnclearYesYesNoNoYes
FAST4WARDFleischmann, 2009YesYesYesYesNoNoYes
RAPID 1Keystone, 2008;
Strand, 2009
UnclearUnclearYesYesNoNoYes
RAPID 2Smolen, 2009;
Strand, 2011
UnclearUnclearYesYesNoNoYes
NCT00544154Choy, 2012YesYesYesYesNoNoYes
ETN–Mathias/MorelandMoreland, 1999;
Mathias, 2000
YesYesYesYesNoNoYes
ETN–WeinblattWeinblatt, 1999YesYesYesYesNoNoUnclear
ADOREVan Riel, 2006; van Riel, 2008UnclearUnclearNoYesNoNoYes
ETN–CombeCombe, 2006;
Combe, 2009
UnclearUnclearYesYesNoNoYes
GLB–KayKay, 2008YesYesYesYesNoNoUnclear
GO–FORWARDKeystone, 2009;
Genovese, 2012
YesYesYesYesNoNoUnclear
ATTRACTLipsky, 2000; Maini, 1999YesYesYesYesNoNoYes
STARTWesthovens, 2006UnclearUnclearYesYesNoNoYes
CHARISMAMaini, 2006YesYesYesYesNoNoYes
OPTIONSmolen, 2008YesYesYesYesNoNoYes
LITHEKremer, 2011;
Fleischmann, 2013
YesYesYesYesNoNoYes
ORAL-Solo (Pfizer A3921045)Fleishmann, 2012YesYesYesYesNoNoYes
TOFA monotherapy (Pfizer A3921035)Fleischmann, 2012UnclearUnclearYesYesNoNoUnclear
ORAL-Standard (Pfizer A3921064)van Vollenhoven, 2012YesYesUnclearYesNoNoUnclear
TOFA+MTX–Kremer (Pfizer A3921025)Kremer, 2012UnclearUnclearYesYesNoNoUnclear
ORAL-Scan (Pfizer A3921044)Van der Heijde, 2013;
van der Heijde, 2012;
van der Heijde, 2011
YesYesYesYesNoNoUnclear

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.